Amyotrophic Lateral Sclerosis Epidemiology Forecast
DelveInsight's ‘Amyotrophic Lateral Sclerosis - Epidemiology Forecast–2032’ report delivers an in-depth understanding of the disease, historical and forecasted Amyotrophic Lateral Sclerosis epidemiology in the United States, EU-4 (Germany, Spain, Italy, and France), the United Kingdom, Japan and China
Geography Covered
- The United States
- EU-4 (Germany, France, Italy,and Spain), the United Kingdom
- Japan
- China
Study Period: 2019-2032
Amyotrophic Lateral Sclerosis Disease Understanding and Treatment Algorithm
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a group of rare neurological diseases that mainly involve the nerve cells (neurons) responsible for controlling voluntary muscle movement. The disease is progressive, meaning the symptoms get worse over time. ALS belongs to a wider group of disorders known as motor neuron diseases caused by gradual deterioration (degeneration) and death of motor neurons. Motor neurons are nerve cells that extend from the brain to the spinal cord and muscles throughout the body. Messages from motor neurons in the brain (called upper motor neurons; UMN) are transmitted to motor neurons in the spinal cord and to motor nuclei of the brain (called lower motor neurons; LMN) and from the spinal cord and motor nuclei of the brain to a particular muscle or muscles. ALS can be either sporadic or genetic. The sporadic type is the most common and can affect anyone. The genetic or familial type is rarer. Common symptoms include painless, progressive muscle weakness. The first thing a person might notice is tripping more often, or dropping things because of the weakness. Slurred speech, difficulty swallowing, and trouble breathing can occur.
Amyotrophic Lateral Sclerosis Diagnosis
ALS is a difficult disease to diagnose. There is no one test or procedure to establish the diagnosis of ALS ultimately. It is through a clinical examination and a series of diagnostic tests, often ruling out other diseases that mimic ALS. The diagnosis of ALS relies on medical history, physical examination, electrodiagnostic testing (with needle EMG), and neuroimaging. Biomarkers can play a crucial role in diagnostic, prognostic, or predictive research studies. They could potentially become important for the stratification of patients and monitoring treatment effects in clinical trials. Genetic testing of the five most prevalent genes found to be mutated in ALS is routinely offered to patients with a positive family history (C9orf72, SOD1, TDP‐43, FUS, and TBK‐1).
Amyotrophic Lateral Sclerosis Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalence of ALS, Diagnosed Prevalence of ALS, Gender-specific Distribution of ALS, Mutation-specific Distribution of ALS, Type-specific Distribution of ALS, Distribution based on Site of onset of ALS, Age-specific Distribution of ALS, in the United States, EU-4 (Germany, Spain, Italy,and France), the United Kingdom, Japan, and China market from 2019 to 2032.
Key Findings
- This section provides glimpse of the Amyotrophic Lateral Sclerosis epidemiology in the United States, EU- 4 (Germany, Spain, Italy, and France), the United Kingdom, Japan, and China
- The total diagnosed prevalent cases of ALS in the 7MM and China were 59,130 and 29,095 in 2021, growing at a CAGR of 1.3% and 0.6% respectively during the study period (2019–2032).
- Epidemiology assessed for the condition showed that the US, in 2021 accounted for approximately 25,817 diagnosed prevalent cases of ALS.
- Among the EU-4 and the United Kingdom countries in 2021, Germany had the highest diagnosed prevalent cases of ALS with 5,398 cases, followed by UK (4,561) and Italy (4,478). In contrast, Spain had the lowest cases (3,270) in 2021.
- Japan accounted for 11,183 diagnosed prevalent ALS cases in 2021.
- In the United States, in 2021, the proportion of male and female cases were 14,948 and 10,869 respectively.
- As per the analysis, a higher percentage of sporadic ALS was observed in the 7MM and China compared to familial ALS in 2021.
- ALS can be divided into C9ORF72, SOD1, FUS, others mutations (TARDBP, OPTN, ANG, etc.), and non-mutated/unidentified mutation based on the types of mutations causing the condition. In the United States, the number of cases of C9ORF72, SOD1, FUS, others mutations (TARDBP, OPTN, ANG, etc.), and non-mutated/unidentified mutation was 2,478, 749, 361, 2,189 and 20,039 respectively, in 2021.
- Japan accounted for approximately 3,892 cases of 70-79 years of age of ALS in 2021.
- In China, in 2021 the proportion of male and female cases were 17,948 and 11,146 respectively.
- In 2021, the patients with the spinal site of onset accounted for 21,035 cases, followed by 5,673 cases with the bulbar site of onset, and 2,386 cases with other uncertain regions in China.
Scope of the Report
- The report covers the descriptive overview of ALS, explaining its causes, signs and symptoms, pathophysiology, and diagnosis
- Comprehensive insight has been provided into the ALS epidemiology in the 7MM and China
- A detailed review of ALS epidem; historical and forecasted is included in the report, covering drug outreach in the 7MM and China
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global ALS market
Report Highlights
- In the coming years, ALS market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence ALS R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for ALS. Launch of emerging therapies will significantly impact the ALS market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for ALS
Amyotrophic Lateral Sclerosis Report Insights
- Patient Population
- Therapeutic Approaches
- ALS Pipeline Analysis
- ALS Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Amyotrophic Lateral Sclerosis Report Key Strengths
- 11 Years Forecast
- 7MM and China Coverage
- ALS Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Amyotrophic Lateral Sclerosis Report Assessment
- Disease Understanding
- Current Diagosis Practices and Guidelines
- Epidemiology Trends
Key Questions
- What is the disease risk, burden and regional/ethnic differences of the ALS?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU-4 (Germany, Spain, Italy, and France), the United Kingdom, Japan, and China?
- What is the historical ALS patient pool in seven major markets covering the United States, EU-4 (Germany, Spain, Italy, and France), the United Kingdom, Japan, and China?
- What would be the forecasted patient pool of ALS in seven major markets covering the United States, EU-4 (Germany, Spain, Italy,and France), the United Kingdom, Japan, and China?
- Where will be the growth opportunities in the 7MM and China with respect to the patient population pertaining to ALS?
- Out of all 7MM and China countries, which country would have the highest prevalent population of ALS during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow in 7MM and China during the forecast period (2019-2032)?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the ALS market
- To understand the future market competition in the ALS market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for ALS in the US, EU-4 (Germany, Spain, Italy, and France), the United Kingdom, Japan, and China
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Epidemiology Methodology
5. Disease Background and Overview
5.1. Introduction
5.2. Types of ALS
5.2.1. Sporadic ALS
5.2.2. Genetic or Familial ALS
5.3. Causes
5.3.1. Genetics
5.3.2. Environmental factors
5.4. Risk factors
5.5. Symptoms
5.6. Clinical Features
5.6.1. Clinical presentation
5.6.2. Amyotrophic lateral sclerosis phenotypes
5.6.3. Subtypes of ALS based on relative UMN versus LMN involvement
5.6.4. Subtypes of motor neuron disease based on the regional distribution of involvement
5.6.5. Subtypes of ALS based on additional frontotemporal involvement
5.7. Pathogenesis
5.7.1. Failure of proteostasis
5.7.2. Disturbed RNA metabolism
5.7.3. Cytoskeletal disturbances and axonal transport defects
5.8. Biomarker
5.9. Prediction of prognosis
5.10. Differential Diagnosis
5.11. Diagnosis
6. Epidemiology and Patient Population of the 7MM and China
6.1. Key Findings
6.2. Assumptions and Rationale
6.3. Total Prevalent Population of Amyotrophic Lateral Sclerosis in the 7MM and China
6.4. Total Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis in the 7MM and China
6.5. United States
6.5.1. Prevalence of Amyotrophic Lateral Sclerosis in the United States
6.5.2. Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in the United States
6.5.3. Gender-specific Distribution of Amyotrophic Lateral Sclerosis in the United States
6.5.4. Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in the United States
6.5.5. Type-specific Distribution of Amyotrophic Lateral Sclerosis in the United States
6.5.6. Distribution Based on Site of Onset of Amyotrophic Lateral Sclerosis in the United States
6.5.7. Age-specific Distribution of Amyotrophic Lateral Sclerosis in the United States
6.6. EU-4 and UK
6.6.1. Prevalence of Amyotrophic Lateral Sclerosis in the EU-4 and the UK
6.6.2. Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in the EU-4 and the UK
6.6.3. Gender-specific Distribution of Amyotrophic Lateral Sclerosis in the EU-4 and the UK
6.6.4. Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in the EU-4 and the UK
6.6.5. Type-specific Distribution of Amyotrophic Lateral Sclerosis in the EU-4 and the UK
6.6.6. Distribution Based on Site of Onset of Amyotrophic Lateral Sclerosis in the EU-4 and the UK
6.6.7. Age-specific Distribution of Amyotrophic Lateral Sclerosis in the EU-4 and the UK
6.7. Japan
6.7.1. Prevalence of Amyotrophic Lateral Sclerosis in Japan
6.7.2. Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in Japan
6.7.3. Gender-specific Distribution of Amyotrophic Lateral Sclerosis in Japan
6.7.4. Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in Japan
6.7.5. Type-specific Distribution of Amyotrophic Lateral Sclerosis in Japan
6.7.6. Distribution Based on Site of Onset of Amyotrophic Lateral Sclerosis in Japan
6.7.7. Age-specific Distribution of Amyotrophic Lateral Sclerosis in Japan
6.8. China
6.8.1. Prevalence of Amyotrophic Lateral Sclerosis in China
6.8.2. Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in China
6.8.3. Gender-specific Distribution of Amyotrophic Lateral Sclerosis in China
6.8.4. Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in China
6.8.5. Type-specific Distribution of Amyotrophic Lateral Sclerosis in China
6.8.6. Distribution Based on Site of Onset of Amyotrophic Lateral Sclerosis in China
6.8.7. Age-specific Distribution of Amyotrophic Lateral Sclerosis in China
7. Appendix
7.1. Bibliography
7.2. Report Methodology
8. DelveInsight Capabilities
9. Disclaimer
10. About DelveInsight
List of Table
Table 1: Summary of Amyotrophic lateral sclerosis (ALS) Market, and Epidemiology (2019–2032)
Table 2: List of differential diagnosis and clinical overlap with ALS
Table 3: Summary table of ALS and key differentiating factors with each mimic/variant
Table 4: Diagnostic tests for ALS
Table 5: Total Prevalent Population of ALS in the 7MM and China (2019–2032)
Table 6: Total Diagnosed Prevalent Population of ALS in the 7MM and China (2019–2032)
Table 7: Prevalence of ALS in the US (2019–2032)
Table 8: Diagnosed Prevalence of ALS in the US (2019–2032)
Table 9: Gender-specific Distribution of ALS in the US (2019–2032)
Table 10: Mutation-specific Distribution of ALS in the US (2019–2032)
Table 11: Type-specific Distribution of ALS in the US (2019–2032)
Table 12: Distribution Based on Site of Onset of ALS in the US (2019–2032)
Table 13: Age-specific Distribution of ALS in the US (2019–2032)
Table 14: Prevalence of ALS in the EU-4 and the UK (2019–2032)
Table 15: Diagnosed Prevalence of ALS in the EU-4 and the UK (2019–2032)
Table 16: Gender-specific Distribution of ALS in the EU-4 and the UK (2019–2032)
Table 17: Mutation-specific Distribution of ALS in the EU-4 and the UK (2019–2032)
Table 18: Type-specific Distribution of ALS in the EU-4 and the UK (2019–2032)
Table 19: Distribution Based on Site of Onset of ALS in the EU-4 and the UK (2019–2032)
Table 20: Age-specific Distribution of ALS in the EU-4 and the UK (2019–2032)
Table 21: Prevalence of ALS in Japan (2019–2032)
Table 22: Diagnosed Prevalence of ALS in Japan (2019–2032)
Table 23: Gender-specific Distribution of ALS in Japan (2019–2032)
Table 24: Mutation-specific Distribution of ALS in Japan (2019–2032)
Table 25: Type-specific Distribution of ALS in Japan (2019–2032)
Table 26: Distribution Based on Site of Onset of ALS in Japan (2019–2032)
Table 27: Age-specific Distribution of ALS in Japan (2019–2032)
Table 28: Prevalence of ALS in China (2019–2032)
Table 29: Diagnosed Prevalence of ALS in China (2019–2032)
Table 30: Gender-specific Distribution of ALS in China (2019–2032)
Table 31: Mutation-specific Distribution of ALS in China (2019–2032)
Table 32: Type-specific Distribution of ALS in China (2019–2032)
Table 33: Distribution Based on Site of Onset of ALS in China (2019–2032)
Table 34: Age-specific Distribution of ALS in China (2019–2032)
List of Figures
Figure 1: Phenotypic presentations of ALS
Figure 2: Clustering of ALS genes in pathogenic pathways
Figure 3: Flowchart for the management of respiratory dysfunction in ALS/ motor neuron disease (MND)
Figure 4: Total Prevalent Population of ALS in the 7MM and China (2019–2032)
Figure 5: Total Diagnosed Prevalent Population of ALS in the 7MM and China (2019–2032)
Figure 6: Prevalence of ALS in the US (2019–2032)
Figure 7: Diagnosed Prevalence of ALS in the US (2019–2032)
Figure 8: Gender-specific Distribution of ALS in the US (2019–2032)
Figure 9: Mutation-specific Distribution of ALS in the US (2019–2032)
Figure 10: Type-specific Distribution of ALS in the US (2019–2032)
Figure 11: Distribution Based on Site of Onset of ALS in the US (2019–2032)
Figure 12: Age-specific Distribution of ALS in the US (2019–2032)
Figure 13: Prevalence of ALS in the EU-4 and the UK (2019–2032)
Figure 14: Diagnosed Prevalence of ALS in the EU-4 and the UK (2019–2032)
Figure 15: Gender-specific Distribution of ALS in the EU-4 and the UK (2019–2032)
Figure 16: Mutation-specific Distribution of ALS in the EU-4 and the UK (2019–2032)
Figure 17: Type-specific Distribution of ALS in the EU-4 and the UK (2019–2032)
Figure 18: Distribution Based on Site of Onset of ALS in the EU-4 and the UK (2019–2032)
Figure 19: Age-specific Distribution of ALS in the EU-4 and the UK (2019–2032)
Figure 20: Prevalence of ALS in Japan (2019–2032)
Figure 21: Diagnosed Prevalence of ALS in Japan (2019–2032)
Figure 22: Gender-specific Distribution of ALS in Japan (2019–2032)
Figure 23: Mutation-specific Distribution of ALS in Japan (2019–2032)
Figure 24: Type-specific Distribution of ALS in Japan (2019–2032)
Figure 25: Distribution Based on Site of Onset of ALS in Japan (2019–2032)
Figure 26: Age-specific Distribution of ALS in Japan (2019–2032)
Figure 27: Prevalence of ALS in China (2019–2032)
Figure 28: Diagnosed Prevalence of ALS in China (2019–2032)
Figure 29: Gender-specific Distribution of ALS in China (2019–2032)
Figure 30: Mutation-specific Distribution of ALS in China (2019–2032)
Figure 31: Type-specific Distribution of ALS in China (2019–2032)
Figure 32: Distribution Based on Site of Onset of ALS in China (2019–2032)
Figure 33: Age-specific Distribution of ALS in China (2019–2032)